Twist Bioscience Corp. Hits New 52-Week High of $86.78

Twist Bioscience Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 86.78 on June 16, 2026. This achievement underscores the company's strong performance over the past year, with a remarkable increase of 69.87%, significantly outpacing the S&P 500's growth of 24.5% during the same period. With a market capitalization of USD 2,730 million, Twist Bioscience operates in a competitive industry characterized by innovation and rapid advancements. The company's financial metrics reveal a price-to-book ratio of 5.99, indicating a premium valuation relative to its book value. However, it is important to note that the company is currently loss-making, as reflected by its negative return on equity of -16.79% and a debt-to-equity ratio of -0.41. As Twist Bioscience continues to navigate the dynamic landscape of biotechnology, its recent price achievement highlights its position within the market and the potential for continued growth in the sector.